🇺🇸 FDA
Patent

US 11667890

Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion

granted A61KA61K2039/515A61K40/11

Quick answer

US patent 11667890 (Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion) held by Iovance Biotherapeutics, Inc. expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Iovance Biotherapeutics, Inc.
Grant date
Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/515, A61K40/11, A61K40/42, A61P